GUARDANT360 TissueNext™ | GUARDANT GALAXY™ PD-L1

A MORE PRECISE

PD-L1 TEST FOR NSCLC[1]

With an AI-backed digital pathology algorithm, part of the new Guardant Galaxy™ technology suite



>20% IMPROVED PD-L1 DETECTION*[1]

AI-powered PD-L1 scoring accurately classified 22.2% of NSCLC patients initially identified as Tumor Proportion Score (TPS) <1%[1]

Scan to read full *European Journal of Cancer* article

ACCURATE SCORING HELPS TO PREDICT RESPONSE TO IMMUNOTHERAPY

In **KEYNOTE-189**, overall response rates ranged from 33.1-62.1% depending on TPS[2]

MULTI-CANCER

NOW VALIDATED FOR MULTIPLE CANCERS

Including breast, colorectal, gastric, hepatobiliary, pancreatic, prostate, and urothelial cancers

1. https://www.ejcancer.com/article/S0959-8049(22)00215-5/fulltext
2. https://www.annalsofoncology.org/article/S0923-7534(21)01146-7/fulltext

*Compared to manual pathologist interpretation in the most challenging cases in NSCLC.
AI: Artificial Intelligence; NSCLC: non-small cell lung cancer

GUARDANT™

Guardant360 TissueNext panel

Covers clinically relevant biomarkers, including TMB, MSI status, and PD-L1. Results are reported 2-3 weeks from sample receipt.

Point Mutations (SNVs) and Deletion Variants (Indels) *(84 Genes)*

AKT1	*ALK*	*APC*	*AR*	*ARAF*	*ARID1A*	*ATM*	***BRAF***
BRCA1	*BRCA2*	*CCND1*	*CCND2*	*CCNE1*	*CDH1*	*CDK4*	*CDK6*
CDK12	*CDKN2A*	*CHEK2*	*CTNNB1*	*DDR2*	***EGFR***	***ERBB2***	*ESR1*
EZH2	*FANCA*	*FBXW7*	*FGFR1*	*FGFR2*	*FGFR3*	*GATA3*	*GNA11*
GNAQ	*GNAS*	*HNF1A*	*HRAS*	*IDH1*	*IDH2*	*JAK2*	*JAK3*
KEAP1	*KIT*	***KRAS***	*MAP2K1*	*MAP2K2*	*MAPK1*	*MAPK3*	***MET***
MLH1	*MPL*	*MSH6*	*MSH2*	*MTOR*	*MYC*	*MYCN*	*NF1*
NFE2L2	*NOTCH1*	*NPM1*	*NRAS*	*NTRK1*	*NTRK2*	*NTRK3*	*PALB2*
PDGFRA	*PIK3CA*	*PMS2*	*PTEN*	*PTPN11*	*RAD51D*	*RAF1*	*RB1*
RET	*RHEB*	*RHOA*	*RIT1*	*ROS1*	*SMAD4*	*SMO*	*STK11*
TERT†	*TP53*	*TSC1*	*VHL*				

Amplifications *(20 Genes)*

AR	*BRAF*
CCND1	*CCND2*
CCNE1	*CDK4*
CDK6	*EGFR*
ERBB2	*ESR1*
FGFR1	*FGFR2*
KIT	*KRAS*
MET	*MYC*
MYCN	*PDGFRA*
PIK3CA	*RAF1*

Fusions *(12 Genes)*

ALK	*MET*
BRAF	***NTRK1***
EGFR	***NTRK2***
FGFR1	***NTRK3***
FGFR2	***RET***
FGFR3	***ROS1***

MSI status
Qualitative result

TMB
Mutations per Megabase

PD-L1 status
AI-powered PD-L1 test now available for multiple cancers^

NSCLC guideline-recommended genes shown in bold.
†Includes *TERT* promoter region

Guardant Access Program

- Patient contacted if out-of-pocket costs for each genomic test >$100
- Financial assistance offered if eligible
- Patient given opportunity to cancel test if financially burdened

For comprehensive support, call **855.698.8887** or email **clientservices@guardanthealth.com**

^Some cases may require conventional determination of PD-L1 status without AI.

Important Note: Guardant360 TissueNext and Guardant Galaxy PD-L1 tests were developed, and their performance characteristics determined by Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity testing. These tests have not been cleared or approved by the US FDA.

MKT-000237 R2

GUARDANT™